News & Events

Lanifibranor

Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH

21 February 2019

Inventiva Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis

18 February 2019

New results on lanifibranor to be presented at the International Liver Congress™ 2019

4 February 2019

Inventiva Announces Two Poster Presentations at the American College of Rheumatology Conference

10 October 2018

Inventiva advances in the development of lanifibranor with the achievement of three key milestones

Inventiva’s lanifibranor found to have good safety profile following first assessment of carcinogenicity studies’ results

Inventiva Announces Positive DSMB Reviews in both NASH and Systemic Sclerosis Phase IIb Trials with Lanifibranor

Inventiva Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes

Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors

Inventiva’s paper on the discovery and synthesis of its panPPAR agonist lanifibranor accepted and published in the Journal of Medicinal Chemistry of the American Chemical Society

Inventiva Announces Positive DSMB Review in Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor

Inventiva’s Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor Completes Enrollment

17 October 2017

1 2

Inventiva’s Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor Completes Enrollment